Abstract: Objective To compare the effects of different sodium-glucose cotransporter 2 inhibitors(SGLT2i)on the prognosis of patients with chronic heart failure by Bayesian network Meta-analysis. Methods CNKI, CBM, Wanfang, VIP, Pubmed, Web of Science, Embase, and Cochrane Library were comprehensively searched with computer. The retrieval time was from the establishment of the database to December 1, 2022. Clinical randomized controlled trials of SGLT2i in the treatment of heart failure were collected. Three researchers independently screened and extracted the data. Inexpensive risk assessments were determined according to the Cochrane Handbook of Systematic Reviews. Heterogeneity test and direct Meta-analysis were performed with RevMan5.4 software, and Bayesian network Meta-analysis was performed with ADDIS1.16.6 software. Results A total of 9 RCTs were included, including 3 different SGLT2i types, involving a total of 23 285 patients. Compared with placebo, the three SGLT2i could significantly reduce the incidence of the composite endpoint of cardiovascular death/heart failure hospitalization, order from superior to inferior was: soxagliflozin>dapagliflozin>empagliflozin>placebo. Compared with placebo, dagliazine alone could reduce the incidence of cardiovascular or all-cause death. There was no statistically significant in reducing incidence of hypoglycemic events between the three SGLT2i and placebo. Conclusion SGLT2i can reduce the incidence of the composite endpoint of cardiovascular death/heart failure hospitalization in patients with chronic heart failure, without increasing the risk of hypoglycemia events, and dapagliflozin may be superior to soxagliflozin and empagliflozin in terms of cardiovascular death and all-cause mortality.

Key words: heart failure, sodium-glucose cotransporter 2 inhibitor, network Meta-analysis